Liver transplantation has become the most efficient treatment for end-stage liver disease. Without prevention, the recurrent rate of hepatitis B post-transplantation is as high as 80%~100%. Most of these patients will undergo acute, chronic hepatitis, then develop liver cirrhosis, liver failure. Second liver transplantation is usually the only choice of the patients. With the development of medicine, Lamivudine is wide used in clinic to prevent and treat hepatitis B. The rate of positive HBV-DNA to negative is about 60%~70%, but, YMDD mutation is about 21%, which compromises the effect of this medicine. The combined use of large dose of HBIG and LAM abroad to prevent the recurrence of hepatitis B has relatively good result, but it is very expensive. Considering the current status of our country, we modified the protocol, using little dose of HBIG combining LAM for the prevention of hepatitis B after liver transplantation. The modified protocol is less expensive yet with very good result (see “PREVENTION AND TREATMENT OF HEPATITIS B RECURREACE AFTER LIVER TRANSPLANTATION” in 《Hepatobiliary & Pancreatic Diseases International》2003, 2).